Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norethindrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.73 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.73 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.73 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norethindrone SCHEMBL23390 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL14577661 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL19510084 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL5021649 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL14074493 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL24476231 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL6834811 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL11781372 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL9161897 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL11291575 | 0.97 | CYP3A4 (0.94) | CYP3A4LMNACYP2C19ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440706-B1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260034147-A1 | COMPOUNDS AND THEIR USES FOR ALLEVIATING MENOPAUSE-ASSOCIATED SYMPTOMS | ESTETRA SRL (BE) | 2026-02-05 | — | — | US | disclosed |
| US-20250360147-A1 | METHODS USING COMBINED ORAL CONTRACEPTIVE COMPOSITIONS WITH REDUCED CARDIOVASCULAR EFFECTS | ESTETRA SRL (BE) | 2025-11-27 | — | — | US | disclosed |
| US-12458651-B2 | Compounds and their uses for alleviating menopause-associated symptoms | ESTETRA SRL (BE) | 2025-11-04 | — | — | US | disclosed |
| EP-4637777-A1 | USE OF ESTETROL IN HEPATICALLY IMPAIRED PATIENTS | Estetra SRL (BE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250325467-A1 | COMPOSITIONS FOR PREVENTING OR TREATING SKIN AGING | ESTETRA SRL (BE) | 2025-10-23 | — | — | US | disclosed |
| US-12390478-B2 | Compounds and their uses for alleviating menopause-associated symptoms | ESTETRA SRL (BE) | 2025-08-19 | — | — | US | disclosed |
| WO-2025061912-A1 | ESTETROL FOR USE IN THE TREATMENT OF FEMALE SEXUAL AROUSAL DISORDER | ESTETRA SRL (BE) | 2025-03-27 | — | — | WO | disclosed |
| US-20250099485-A1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2025-03-27 | — | — | US | disclosed |
| WO-2024133210-A1 | USE OF ESTETROL IN HEPATICALLY IMPAIRED PATIENTS | ESTETRA SRL (BE) | 2024-06-27 | — | — | WO | disclosed |
| CN-101208107-A | Quadraphasis continuous graduated estrogen contraceptive | WARNER CHILCOTT CO INC (US) | 2008-06-25 | — | — | CN | disclosed |
| CN-1878558-A | Gradient estrogen contraceptive | WARNER CHILCOTT CO INC (US) | 2006-12-13 | — | — | CN | disclosed |
| EP-0253607-B2 | Combination dosage form for premenopausal women | AMERICAN HOME PROD (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0682672-A1 | STEROIDS FOR TREATING MENOPAUSAL COMPLAINTS | Akzo Nobel N.V. (NL) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994018224-A1 | STEROIDS FOR TREATING MENOPAUSAL COMPLAINTS | AKZO NOBEL N.V. (NL) | 1994-08-18 | — | — | WO | disclosed |
| EP-0253607-B1 | COMBINATION DOSAGE FORM FOR PREMENOPAUSAL WOMEN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-29 | — | — | EP | disclosed |
| US-5094857-A | TREATMENT OF ACNE OR ANDROGENETIC ALOPECIA BY TOPICAL ADMINISTRATION OF ETHISTERONE | LUDERSCHMIDT CHRISTOPH (DE) | 1992-03-10 | — | — | US | disclosed |
| EP-0316780-A1 | Use of ethisterone in the topical treatment of acne or androgenetic alopecia | Luderschmidt, Christoph, Prof. Dr. med. (DE) | 1989-05-24 | — | — | EP | disclosed |
| WO-1988000469-A1 | COMBINATION DOSAGE FORM FOR PRE-MENOPAUSAL WOMEN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-01-28 | — | — | WO | disclosed |
| EP-0253607-A1 | Combination dosage form for premenopausal women | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099485-A1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | FGF1, HDGF, NGF | PGR 1857/4885CYP3A4 4572/4885LMNA 2652/4885 |
| US-20260034147-A1 | COMPOUNDS AND THEIR USES FOR ALLEVIATING MENOPAUSE-ASSOCIATED SYMPTOMS | PGR, SHBG, CYP19A1 | PGR 1/4885CYP3A4 1078/4885LMNA 3009/4885 |
| US-20250325467-A1 | COMPOSITIONS FOR PREVENTING OR TREATING SKIN AGING | GLA, CUTA, ERCC1 | PGR 1252/4885CYP3A4 3399/4885LMNA 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.